The company was founded in 1999 and listed on the Shenzhen Stock Exchange in 2022. The company is committed to providing CDMO services for multinational pharmaceutical companies and pharmaceutical R&D institutions such as process development and optimization, quality research and customized production of key pharmaceutical intermediates and APIs in the clinical trial and commercialization stages. The terminal drugs cover various treatment fields such as antitumor, antiviral, neurological, and diabetes. The company's main business covers providing CDMO R&D and production services for key pharmaceutical intermediates and pharmaceutical R&D institutions, R&D, production and sales of L-carnitine series products and APIs, and R&D of stem cell drugs for multinational pharmaceutical companies and pharmaceutical R&D institutions. The company's main products are L-carnitine, L-carnitine hydrochloride, acetyl L-carnitine hydrochloride, DL-carnitine hydrochloride, L-carnitine tartrate, L-carnitine fumarate, L-carnitine (50%), and raw materials. Corporate honors: In 2023, it won the second batch of benchmark projects in Zhejiang Province - pollution reduction and carbon reduction project, Jiaxing city fire “five advanced” pilot units, Jiaxing key enterprise compliance construction pilot units, the 17th Jiashan County Mayor Quality Award, high-tech enterprise certificate, national key new product (L-carnitine) certificate, “Yangtze River Delta Ecological Green Integrated Development Demonstration Zone Green Development Leading Enterprise”, the 2024 Zhejiang Green Low-carbon Factory, Jiashan County “Safety Production Demonstration Enterprise”, etc.